Sun Pharmaceutical vs Mankind Pharma: share price, P/E, ROE and financials compared
Sun Pharmaceutical Industries
Mankind Pharma
Sun Pharmaceutical and Mankind Pharma at a glance
Sun Pharmaceutical and Mankind Pharma are both listed in Healthcare. Sun Pharmaceutical is the larger by market cap, at ₹4.5L Cr against ₹1.0L Cr for Mankind Pharma (4.3 times as large). On valuation, Sun Pharmaceutical has the lower P/E (40.7× against 46.8×) and the lower price-to-book (4.99× against 5.97×). On returns and margins, Sun Pharmaceutical has the higher ROCE (17.9% against 13.7%) and the higher operating margin (28.2% against 26.5%). Over three years, Mankind Pharma has faster 3-year sales growth (+17.7% against +10.4% a year) and faster 3-year profit growth (+14.3% against +10.6% a year). Sun Pharmaceutical carries less debt for its equity, with a debt-to-equity of 0.04× against 0.30×.
Key metrics, side by side
| Metric | Sun PharmaceuticalSUNPHARMA | Mankind PharmaMANKIND |
|---|---|---|
| Price (₹) | 1,860.00 | 2,540.00 |
| Market cap (₹ Cr) | 4,46,276 | 1,04,913 |
| P/E | 40.7× (the lower figure, shaded) | 46.8× |
| P/B | 4.99× (the lower figure, shaded) | 5.97× |
| Dividend yield, trailing | 0.86% (the higher figure, shaded) | 0.00% |
| ROE | 13.1% | 13.6% |
| ROCE | 17.9% (the higher figure, shaded) | 13.7% |
| Operating margin (OPM) | 28.2% (the higher figure, shaded) | 26.5% |
| Net margin (NPM) | 17.8% (the higher figure, shaded) | 14.6% |
| Sales CAGR 3Y | +10.4% | +17.7% (the higher figure, shaded) |
| Profit CAGR 3Y | +10.6% | +14.3% (the higher figure, shaded) |
| Debt to equity | 0.04× (the lower figure, shaded) | 0.30× |
| Interest cover | 45.6× (the higher figure, shaded) | 4.7× |
| Net profit TTM (₹ Cr) | 10,966 | 2,243 |
| 1Y return | +8.2% (the higher figure, shaded) | +6.3% |
| Promoter holding | 52.68% | 72.62% |
Sun Pharmaceutical vs Mankind Pharma: common questions
Which is bigger, Sun Pharmaceutical or Mankind Pharma?
By market cap, Sun Pharmaceutical is bigger at ₹4.5L Cr, against ₹1.0L Cr for Mankind Pharma (prices as of 6 Nov 2026). Net profit over the last twelve months was ₹10,966 Cr for Sun Pharmaceutical and ₹2,243 Cr for Mankind Pharma.
Which has a lower P/E ratio, Sun Pharmaceutical or Mankind Pharma?
Sun Pharmaceutical trades at a P/E of 40.7× and Mankind Pharma at 46.8×. Sun Pharmaceutical has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Sun Pharmaceutical or Mankind Pharma?
Sun Pharmaceutical reports a return on equity of 13.1% and Mankind Pharma 13.6%. The two are close. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Sun Pharmaceutical or Mankind Pharma?
Over the last three years: Sales grew +10.4% a year at Sun Pharmaceutical and +17.7% at Mankind Pharma, so Mankind Pharma grew sales faster; profit grew +10.6% a year at Sun Pharmaceutical and +14.3% at Mankind Pharma, so Mankind Pharma grew profit faster. Past growth doesn’t predict future growth.